Press releases
- ViiV Healthcare presents positive new findings from two studies of its investigational, long-acting regimen of cabotegravir and rilpivirine, including five-year data showing long-term durability, efficacy, safety, and tolerability
- ViiV Healthcare presents continued positive findings from first-ever implementation science study on integrating an investigational once-monthly injectable HIV treatment into US healthcare practices
- ViiV Healthcare announces analysis showing no antiretroviral therapy interruptions due to COVID-19 across its clinical development programme for investigational, long-acting cabotegravir and rilpivirine
Tweets from GSK US
-
GSKUS @GSKUS
The best way to help protect against flu is to #GetVaccinated each year. Our own Dr. Leonard Freeland, VP & Director, Scientific Affairs & Public Health, Vaccines is #leadingbyexample by getting his flu shot this week. 💉We are proud to#FightFluu along with@NFIDvacciness!
about 26 days ago
A
-
GSKUS @GSKUS
It’s time to #OvaryAct in honor of #OvarianCancerAwarenessMonth. Get to know the signs and symptoms of #ovariancancer, and if you’re experiencing any of them make sure to speak with your doctor. Watch the video below and learn more 👇gsk.to/2GhrHDrjd
about 26 days ago -
GSKUS @GSKUS
Following the events of #racialinjustice in the US, we’ve been focused on #listeningtounderstand to identify where we can do more and focus on the things that’ll drive change in our company. Hear more from Carla, our VP, Specialty Marketing, US Pharma. #TuesdayThoughts
about 27 days ago
